Abstract
Background Transmission of HIV-1 across mucosal surfaces is the most prevalent mode of viral infection. Therefore, a successful vaccine must induce broad anti-viral immunity at the mucosal surface. In the present study, we investigated the immunogenicity of a novel Lactobacillus gasseri mucosal vaccine vector for use in oral delivery of HIV antigens. L. gasseri was genetically engineered to express Salmonella spp. flagellin (L. gasseri-FliC) – the agonist for Toll-like receptor 5 (TLR5) and a potent activator of innate immune cells.
Highlights
Transmission of HIV-1 across mucosal surfaces is the most prevalent mode of viral infection
We investigated the immunogenicity of a novel Lactobacillus gasseri mucosal vaccine vector for use in oral delivery of HIV antigens
To evaluate the potential adjuvant activity of our vector, we determined the ability of L. gasseri-FliC to induce myeloid dendritic cell (DC) activation as measured by phenotypic activation and cytokine production
Summary
Immunogenicity of Lactobacillus gasseri-FliC as an oral mucosal vaccine adjuvant for HIV. Address: 1Molecular Biomedical Sciences, CCMTR, North Carolina State University College of Veterinary Medicine, Raleigh, NC, USA and 2Department of Food, Bioprocessing and Nutritional Sciences, NCSU, Raleigh, NC, USA. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P163 doi:10.1186/1742-4690-6-S3-P163. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
